Hyaluronic Acid
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Hyaluronic Acid: From Multi-Purpose Biopolymer to Dry Eye Syndrome
One-Sentence Summary
Hyaluronic acid (DrugBank DB08818) has no single registered original indication on file — it is a naturally occurring glycosaminoglycan used across ophthalmic, dermal, and orthopedic formulations worldwide. The TxGNN model predicts it may be effective for Dry Eye Syndrome, a use already extensively supported by 50 clinical trials and 20 publications identified in this evidence pack, though the product is currently not marketed in this jurisdiction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No single registered indication on file (Hyaluronic acid is a multi-purpose biopolymer used in ophthalmic, dermal, and orthopedic products globally) |
| Predicted New Indication | Dry Eye Syndrome |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L1 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this entry. Based on well-established pharmacological knowledge, hyaluronic acid is a naturally occurring glycosaminoglycan found endogenously in ocular tissue (aqueous humor, vitreous, and tear film). Its high molecular weight and hygroscopic, viscoelastic properties allow it to bind water, stabilize the tear film, reduce surface friction, and promote corneal epithelial healing — properties that are the pharmacological basis for its widespread use as an artificial-tear component.
Because hyaluronic acid has no single “original” therapeutic indication registered for this DrugBank entry, the TxGNN prediction is less a novel repurposing hypothesis and more a reflection of an already well-validated global use: HA-based ophthalmic solutions (e.g., Vismed®, Hylo-Forte®, Thealoz® Duo) are marketed in many countries specifically for dry eye syndrome and Sjögren-associated keratoconjunctivitis sicca. The prediction therefore aligns closely with real-world practice, and the key open question for this jurisdiction is regulatory/market entry rather than mechanistic plausibility.
The mechanistic rationale extends naturally to the other top-ranked predictions (Sjögren syndrome, xerophthalmia) since these are all disorders of tear-film/mucosal surface hydration where HA’s lubricating and epithelial-repair properties are directly applicable.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00599716 | Phase 3 | Completed | 300 | Multicenter, double-masked RCT of Vismed® (sodium hyaluronate) vs. vehicle for dry eye syndrome |
| NCT01240382 | Phase 3 | Completed | 332 | Confirmatory double-masked comparison of 3% DE-089 vs. 0.1% sodium hyaluronate; superiority on Rose Bengal score |
| NCT05411367 | Phase 3 | Completed | 232 | Multicenter, randomized, double-masked, placebo-controlled trial of SI-614 ophthalmic solution in dry eye |
| NCT03223909 | Phase 4 | Completed | 326 | PRO-087 vs. Systane® Ultra (with/without preservative) for mild-to-moderate tear film dysfunction |
| NCT01101984 | NA (multinational) | Completed | 400 | DE-089 ophthalmic solution vs. 0.1% sodium hyaluronate in dry eye patients |
| NCT03368404 | NA | Completed | 92 | CBL-102 non-inferiority vs. Vismed® Multi in moderate-to-severe keratoconjunctivitis sicca |
| NCT04803240 | N/A | Completed | 310 | Multi-centre, international survey of Thealoz® Duo satisfaction after 84 days of daily treatment |
| NCT00809198 | Phase 4 | Completed | 67 | Randomized, masked comparison of Kynex vs. Refresh Plus in mild-to-moderate dry eye |
| NCT06375499 | NA | Completed | 74 | Non-inferiority of T2769 vs. Hylo-Forte® on ocular surface staining in moderate-severe dry eye |
| NCT04704531 | Phase 2 | Completed | 141 | Comparative dosing regimens of Multidose Lagricel® Ofteno (0.4% sodium hyaluronate) in mild-to-severe dry eye |
(40+ additional trials, including several currently recruiting Phase 4 studies, were identified but omitted here for brevity.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39260878 | 2024 | RCT | BMJ | Non-inferiority RCT: laughter exercise vs. 0.1% sodium hyaluronic acid for ocular surface discomfort in dry eye |
| 34843023 | 2022 | RCT | Japanese Journal of Ophthalmology | Randomized multicenter evaluation of sequential 0.3%/0.15% HA application for dry eye treatment |
| 38895674 | 2024 | Systematic Review/Meta-analysis | International Journal of Ophthalmology | Comparison of HA eye drop concentrations for dry eye syndrome |
| 33804439 | 2021 | Meta-analysis | Int J Environ Res Public Health | Meta-analysis confirming efficacy of HA vs. non-HA eye drops for dry eye syndrome |
| 35514082 | 2022 | Review | Acta Ophthalmologica | Critical review of safety and efficacy literature on HA-containing artificial tears in DED |
| 37042308 | 2024 | Review | Acta Ophthalmologica | Comparison of HA against other single-ingredient eye drops used as DED comparators |
| 39219040 | 2024 | Review | Acta Ophthalmologica | Review of HPMC artificial tears, using HA as an efficacy/safety benchmark |
| 37117131 | 2023 | Clinical Study | Contact Lens & Anterior Eye | Trehalose + HA artificial tears efficacy by age/menopausal status in women with DED |
| 34562113 | 2022 | Clinical Study | Graefe’s Archive for Clinical and Experimental Ophthalmology | HA 0.3% + cyanocobalamin + electrolytes efficacy in menopausal moderate DED |
| 32070808 | 2020 | Review | Carbohydrate Research | Review of HA applications in ophthalmology (dry eye), rheumatology, and dermatology |
India Market Information
No registered marketing authorizations were found for this Hyaluronic acid (DB08818) entry — consistent with the recorded market status of Not marketed and 0 total licenses.
Safety Considerations
Drug Interactions:
| Interacting Drug | Severity Level | Source |
|---|---|---|
| Cetylpyridinium (topical) | Moderate | DDInter |
| Benzalkonium (topical) | Moderate | DDInter |
Both flagged interactions involve topical antiseptic co-formulants (common preservatives in some eye/oral care products) rather than systemic agents; clinical relevance to a standalone HA ophthalmic solution should be confirmed once formulation details are available.
Key warnings and contraindications are not currently available for this entry (data gap DG001).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted indication is backed by L1-level evidence (multiple completed Phase 3 RCTs) and reflects an already well-established global use of hyaluronic acid as an artificial tear for dry eye syndrome. However, this specific product has zero local registrations and a blocking data gap on TFDA-equivalent label warnings/contraindications, which prevents a full safety (S1) assessment at this time.
To proceed, the following is needed:
- Local drug label / package insert data (warnings, contraindications) — currently blocking (DG001)
- Mechanism of action detail from DrugBank API — currently a high-severity gap (DG002)
- Confirmation of intended formulation/route (ophthalmic solution) to assess relevance of the identified topical-antiseptic DDIs
- Local regulatory pathway assessment given current “not marketed” / zero-registration status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.